Ocoxin Oral Solution Exerts an Antitumoral Effect in Pancreatic Cancer and Reduces the Stromal-Mediated Chemoresistance

Autor: Eduardo Sanz, Aitor Benedicto, Elvira Olaso, Irene Romayor, Iera Hernandez-Unzueta, Joana Marquez, Beatriz Arteta, Alba Herrero
Rok vydání: 2019
Předmět:
Male
Endocrinology
Diabetes and Metabolism
Cell
pancreatic cancer
nutritional supplements
Administration
Oral
Ascorbic Acid
Deoxycytidine
Pantothenic Acid
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Pancreatic tumor
CAFs
Cell Cycle
Cell cycle
PSCs
Gene Expression Regulation
Neoplastic
Solutions
Vitamin B 12
medicine.anatomical_structure
Paclitaxel
030220 oncology & carcinogenesis
ComputingMethodologies_DOCUMENTANDTEXTPROCESSING
Adenocarcinoma
030211 gastroenterology & hepatology
medicine.drug
Stromal cell
Cell Survival
Antineoplastic Agents
Cell Line
03 medical and health sciences
Folic Acid
Pancreatic cancer
Cell Line
Tumor
Internal Medicine
medicine
stroma
Animals
Humans
Hepatology
business.industry
Plant Extracts
Gene Expression Profiling
Neoplasms
Experimental
Original Articles
medicine.disease
Gemcitabine
Vitamin B 6
Zinc Sulfate
OOS
Mice
Inbred C57BL
Pancreatic Neoplasms
chemistry
Drug Resistance
Neoplasm
Cancer research
business
Zdroj: Pancreas
ISSN: 1536-4828
Popis: Supplemental digital content is available in the text.
Objectives Pancreatic carcinoma is one of the most aggressive cancers overcoming chemoresistance. Thus, novel compounds to complement the current antitumor agents are in need. Ocoxin oral solution (OOS) has proven antioxidant, anti-inflammatory, and antistromagenic properties. The aim of this study was to analyze the effect of OOS in an experimental pancreatic cancer model and its implication in stroma-related chemoresistance to paclitaxel and gemcitabine. Methods Murine pancreatic carcinoma 266-6 cells were treated with OOS to analyze cell cycle and to perform a mRNA comparative microarray study. Then the viability was assessed in combination with paclitaxel and/or gemcitabine. Chemoresistance induced by the medium taken from fibroblast cultures was also investigated on 6 human pancreatic carcinoma cell lines. Furthermore, an experimental model of pancreatic cancer was carried out to study the effect of OOS in vivo. Results Ocoxin oral solution enhances the cytotoxic effect of paclitaxel and gemcitabine, while it ameliorates the chemoresistance induced by fibroblast-derived soluble factors in human pancreatic cancer cells. The OOS also promotes the regulation of the expression of genes that are altered in pancreatic carcinoma and slows down 266-6 cell pancreatic tumor development in vivo. Conclusions Ocoxin oral solution could be a potential complement to the chemotherapeutic drugs for pancreatic adenocarcinoma.
Databáze: OpenAIRE
Externí odkaz: